Abstract
Telaprevir, a protease inhibitor, was recently approved for management of Chronic Hepatits C (CHC) due to HCV genotype 1. Various RCTs have demonstarted increased incidence of cutaneous adverse effects with use of Telaprevir. Herein, we report two cases of drug rash with eosinophilia and systemic symptoms (DRESS) secondary to Telaprevir use.
MeSH terms
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use
-
Drug Hypersensitivity Syndrome / etiology*
-
Genotype
-
Hepacivirus / genetics
-
Hepatitis C, Chronic / drug therapy
-
Hepatitis C, Chronic / virology
-
Humans
-
Male
-
Middle Aged
-
Oligopeptides / adverse effects*
-
Oligopeptides / therapeutic use
-
Protease Inhibitors / adverse effects*
-
Protease Inhibitors / therapeutic use
Substances
-
Antiviral Agents
-
Oligopeptides
-
Protease Inhibitors
-
telaprevir